ДИАГНОСТИКА, ЛЕЧЕНИЕ И ПРОФИЛАКТИКА ГИНЕКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ

Ergasheva  Zumrad  Abdukayumovna; Soatova  Nargiza  Ergashaliyevna; Nazirjonov  Orifxuja  Xusanxuja ogli; Nugmanov  Ozodbek  Joraboy ogli

doi:10.24411/2181-0443/2020-10123

509

Профилактика заболеваний в гинекологии может быть улучшена за счет улучшения здоровья и лучшего понимания лечения заболеваний. Описательный анализ исследования был проведен в нескольких статьях, опубликованных в медицинских журналах и книгах. Прогнозировать и планировать, организовывать, командовать, координировать и управлять. Если мы введем следующее определение в смысле медицинской науки и применим его в медицинской практике, можно будет распознавать, управлять и решать проблемы диагностики и лечения заболеваний (в данном случае гинекологических заболеваний) в соответствии с определенными руководящими принципами и алгоритмами лечения.означает методы.

Журнал номиRE-HEALTH
Нашр номи3.2-2020
Кўришлар сони 509

Internet ҳавола https://cyberleninka.ru/article/n/diagnostika-lechenie-i-profilaktika-ginekologicheskih-zabolevaniy

DOI10.24411/2181-0443/2020-10123

UzSCI тизимида яратилган сана 31-01-2021

Ўқишлар сони 450

Нашр санаси 31-01-2021

Мақола тилиRus

Саҳифалар сониДИАГНОСТИКА, ЛЕЧЕНИЕ И ПРОФИЛАКТИКА ГИНЕКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ

Калит сўзлар

Репродуктивная

первичная профилактика

Русский

Профилактика заболеваний в гинекологии может быть улучшена за счет улучшения здоровья и лучшего понимания лечения заболеваний. Описательный анализ исследования был проведен в нескольких статьях, опубликованных в медицинских журналах и книгах. Прогнозировать и планировать, организовывать, командовать, координировать и управлять. Если мы введем следующее определение в смысле медицинской науки и применим его в медицинской практике, можно будет распознавать, управлять и решать проблемы диагностики и лечения заболеваний (в данном случае гинекологических заболеваний) в соответствии с определенными руководящими принципами и алгоритмами лечения.означает методы.

Калит сўзлар

Репродуктивная

первичная профилактика

Ўзбек

Ginekologiya bu ayollarning reproduktiv tizimi kasalliklarin idavolash, diagnostikava oldini olish vazifalarini bajaruvchi mutaxassislik. Ginekologiya dakasalliklarning oldini olish sog'liqni saqlashni yaxshilash va kasalliklarni boshqarishni yaxshiroq tushunish orqali yaxshilanish imumkin. Tibbiy jurnallarda va kitoblarda chop etilgan bir necht amaqolalarda ilmiy tadqiqotlar bo'yicha tavsifiy tahlil o'tkazildi. Oldindan taxmin qilish va rejalashtirish, tartibga solish, buyruq berish, muvofiqlashtirish va boshqarish. Agar biz tibbiyot ilmi ma'nosida quyidagi ta'rifni joriy etsak va un itibbiyotamaliyotidaqo'llasak, bu ma'lum ko'rsatmalar va davolash algoritmlariga muvofiq kasalliklarni (buholdaginekologikkasalliklarni) diagnostika va davolash masalalarini tanib olish, boshqarish va hal qilish usullarini anglatadi.

Калит сўзлар

reproduktiv

birlamchiprofilaktika

English

Gynecology is the treatment, diagnosis and prevention of diseases of the female reproductive system. Prevention of diseases in gynecology can be improved by better understanding of health promotion and management of diseases. A descriptive analysis was performed on scientific studies in several published articles in medical journals and books. Anticipate and plan, organize, command, coordinate and control. If we introduce the following definition in the sense of medical science and apply it to the medical practice that would mean way of recognizing, managing and resolving issues of diagnosis and therapy of diseases (in this case gynecology diseases) according to certain guidelines and treatment algorithms.

Калит сўзлар

reproductive

primary prevention

№ Муаллифнинг исми Лавозими Ташкилот номи

1 Ergasheva Z.A. . ASMI

2 Soatova N.E. . ASMI

3 Nazirjonov O.X. . ASMI

4 Nugmanov O.J. . ASMI

№ Ҳавола номи

1 1. Taghavipour, M., Sadoughi, F., Mirzaei, H., Yousefi, B., Moazzami, B., Chaichian, S., …Asemi, Z. (2020). Apoptotic functions of microRNAs in pathogenesis, diagnosis, and treatment of endometriosis. Cell & Bioscience, 10(1). doi:10.1186/s13578-020-0381-0.

2 2. Chen H, Xu Z, Liu D. Small non-coding RNA and colorectal cancer. J Cell Mol Med. 2019;23:3050–7.

3 3. Hu W, Coller J. What comesfrst: translational repression or mRNA degradation? The deepening mystery of microRNA function. Cell Res. 2012;22:1322

4 4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

5 5. Hutvágner G, McLachlan J, Pasquinelli AE, Bálint É, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA.Science. 2001;293:834–8.

6 6. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song J-J, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004;305:1437–41.

7 7. Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H, et al. The muscle-specifc microRNAs miR-1 and miR-133 produce opposing efects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci. 2007;120:3045–52.

8 8. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, et al. A MicroRNA feedback circuit in midbrain dopamine neurons.Science. 2007;317:1220–4.

9 9. Pan Q, Chegini N. MicroRNA signature and regulatory functions in the endometrium during normal and disease states. SeminReprod Med. 2008;26:479–93.

10 10. Jabbour HN, Kelly RW, Fraser HM, Critchley HO. Endocrine regulation of menstruation. Endocr Rev. 2006;27:17–46.

11 11. Achache H, Revel A. Endometrial receptivity markers, the journey to successful embryo implantation. Hum Reprod Update. 2006;12:731–46.

12 12. Lim KJ, Odukoya OA, Ajjan RA, Li T-C, Weetman AP, Cooke ID. The role of T-helper cytokines in human reproduction.FertilSteril. 2000;73:136–42.

13 13. Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ. 2014;348:g1752

14 14. Ballard K, Seaman H, Vries CS, Wright J. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case–control stud.BLOG. 2008;115:1382–91

15 15. Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. ObstetrGynecolClin. 2012;39:535–49.

16 16. Matias-Guiu X, Stewart CJR. Endometriosis-associated ovarian neoplasia.Pathology. 2018;50:190–204.

17 17. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012;27:1292–9.

18 18. Matias-Guiu X, Stewart CJR. Endometriosis-associated ovarian neoplasia.Pathology. 2018;50:190–204.

19 19. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012;27:1292–9.

20 20. Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10:261.

21 21. Baldi A, Campioni M, Signorile PG. Endometriosis: pathogenesis, diagnosis, therapy and association with cancer. Oncol Rep. 2008;19:843–6.

22 22. Burney RO, Giudice LC.Pathogenesis and pathophysiology of endometriosis.FertilSteril. 2012;98:511–9.

23 23. Sasson IE, Taylor HS. Stem cells and the pathogenesis of endometriosis. Ann N Y Acad Sci. 2008;1127:106.

24 24. Watson CN, Belli A, Di Pietro V. Small non-coding RNAs: new class of biomarkers and potential therapeutic targets in neurodegenerative disease. Front Genet. 2019;10:364.

25 25. Santamaria X, Taylor H. MicroRNA and gynecological reproductive diseases. FertilSteril. 2014;101:1545–51.

26 26. Ma, S.-G., Hu, J., & Huang, Y. (2020). The risk factors for perioperative venous thromboembolism in patients with gynecological malignancies: A meta-analysis. Thrombosis Research, 196, 325–334. doi:10.1016/j.thromres.2020.09.019

27 27. Kurt Benirschke, Peter Kaufmann. Pathology of the Human Placenta.doi: 10.1007/978-1-4757-4199-5_10.

28 28. Baldisserotto, M., Spolidoro, J. V. N., &Bahú, M. da G. S. (2002). Graded Compression Sonography of the Colon in the Diagnosis of Polyps in Pediatric Patients. American Journal of Roentgenology, 179(1), 201–205. doi:10.2214/ajr.179.1.1790201.

29 29. G L Grismondi, C Cetera, M Casetti. Polyps of the cervical canal.https://www.ncbi.nlm.nih.gov/pubmed/7366889.

30 30. Xi, L. F., Hughes, J. P., Edelstein, Z. R., Kiviat, N. B., Koutsky, L. A., Mao, C., … Schiffman, M. (2009). Human Papillomavirus (HPV) Type 16 and Type 18 DNA Loads at Baseline and Persistence of Type‐Specific Infection during a 2‐Year Follow‐Up. The Journal of Infectious Diseases, 200(11), 1789–1797. doi:10.1086/647993.

31 31. (1)Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today.

32 32. Xi, L. F., Hughes, J. P., Edelstein, Z. R., Kiviat, N. B., Koutsky, L. A., Mao, C., … Schiffman, M. (2009). Human Papillomavirus (HPV) Type 16 and Type 18 DNA Loads at Baseline and Persistence of Type‐Specific Infection during a 2‐Year Follow‐Up. The Journal of Infectious Diseases, 200(11), 1789–1797. doi:10.1086/647993.

33 33. Machalek, D. A., Garland, S. M., Brotherton, J. M. L., Bateson, D., McNamee, K., Stewart, M., … Tabrizi, S. N. (2018). Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination. The Journal of Infectious Diseases, 217(10), 1590–1600. doi:10.1093/infdis/jiy075.

34 34. Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., … Barr, E. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. The Lancet Oncology, 6(5), 271–278. doi:10.1016/s1470-2045(05)70101-7.

35 35. Matteson, K. A., &Zaluski, K. M. (2019). Menstrual Health as a Part of Preventive Health Care. Obstetrics and Gynecology Clinics of North America, 46(3), 441–453. doi:10.1016/j.ogc.2019.04.004

36 36. ACOG Committee Opinion No. 651: menstruation in girls and adolescents: using the menstrual cycle as a vital sign. ObstetGynecol 2015;126(6):e143–6.

37 37. ACOG annual well-woman exam infographic. Available at: https://www.acog.org/Patients/FAQs/Annual-Well-Woman-Exam-Infographic. Accessed January 4,2019.

38 38. Tingen CM, Mazloomdoost D, Halvorson L. Gynecologic health and disease research at the Eunice Kennedy Shriver National Institute of Child Health and Human Development, A scientific vision. ObstetGynecol 2018;132:987–98.

39 39. Munro M, Critchley H, Broder M, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J GynecolObstet 2011;113(1):3–13.

40 40. Munro MG, Critchley HO, Fraser IS, FIGO Menstrual Disorders Working Group. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years.FertilSteril 2011;95(7):2204–8.

41 41. Munro MG, Critchley HOD, Fraser IS, et al. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J GynecolObstet 2018;143(3):393–408.

42 42. Matteson KA, Boardman LA, Munro MG, et al. Abnormal uterine bleeding: a review of patient-based outcome measures. FertilSteril 2009;92(1):205–16.

43 43. Matteson KA, Scott DM, Raker CA, et al. The menstrual bleeding questionnaire: development and validation of a comprehensive patient-reported outcome instrument for heavy menstrual bleeding. BJOG 2015;122(5):681–9.

Кутилмоқда

№	Муаллифнинг исми	Лавозими	Ташкилот номи
1	Ergasheva Z.A.	.	ASMI
2	Soatova N.E.	.	ASMI
3	Nazirjonov O.X.	.	ASMI
4	Nugmanov O.J.	.	ASMI

№	Ҳавола номи
1	1. Taghavipour, M., Sadoughi, F., Mirzaei, H., Yousefi, B., Moazzami, B., Chaichian, S., …Asemi, Z. (2020). Apoptotic functions of microRNAs in pathogenesis, diagnosis, and treatment of endometriosis. Cell & Bioscience, 10(1). doi:10.1186/s13578-020-0381-0.
2	2. Chen H, Xu Z, Liu D. Small non-coding RNA and colorectal cancer. J Cell Mol Med. 2019;23:3050–7.
3	3. Hu W, Coller J. What comesfrst: translational repression or mRNA degradation? The deepening mystery of microRNA function. Cell Res. 2012;22:1322
4	4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
5	5. Hutvágner G, McLachlan J, Pasquinelli AE, Bálint É, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA.Science. 2001;293:834–8.
6	6. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song J-J, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004;305:1437–41.
7	7. Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H, et al. The muscle-specifc microRNAs miR-1 and miR-133 produce opposing efects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci. 2007;120:3045–52.
8	8. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, et al. A MicroRNA feedback circuit in midbrain dopamine neurons.Science. 2007;317:1220–4.
9	9. Pan Q, Chegini N. MicroRNA signature and regulatory functions in the endometrium during normal and disease states. SeminReprod Med. 2008;26:479–93.
10	10. Jabbour HN, Kelly RW, Fraser HM, Critchley HO. Endocrine regulation of menstruation. Endocr Rev. 2006;27:17–46.
11	11. Achache H, Revel A. Endometrial receptivity markers, the journey to successful embryo implantation. Hum Reprod Update. 2006;12:731–46.
12	12. Lim KJ, Odukoya OA, Ajjan RA, Li T-C, Weetman AP, Cooke ID. The role of T-helper cytokines in human reproduction.FertilSteril. 2000;73:136–42.
13	13. Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ. 2014;348:g1752
14	14. Ballard K, Seaman H, Vries CS, Wright J. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case–control stud.BLOG. 2008;115:1382–91
15	15. Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. ObstetrGynecolClin. 2012;39:535–49.
16	16. Matias-Guiu X, Stewart CJR. Endometriosis-associated ovarian neoplasia.Pathology. 2018;50:190–204.
17	17. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012;27:1292–9.
18	18. Matias-Guiu X, Stewart CJR. Endometriosis-associated ovarian neoplasia.Pathology. 2018;50:190–204.
19	19. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012;27:1292–9.
20	20. Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10:261.
21	21. Baldi A, Campioni M, Signorile PG. Endometriosis: pathogenesis, diagnosis, therapy and association with cancer. Oncol Rep. 2008;19:843–6.
22	22. Burney RO, Giudice LC.Pathogenesis and pathophysiology of endometriosis.FertilSteril. 2012;98:511–9.
23	23. Sasson IE, Taylor HS. Stem cells and the pathogenesis of endometriosis. Ann N Y Acad Sci. 2008;1127:106.
24	24. Watson CN, Belli A, Di Pietro V. Small non-coding RNAs: new class of biomarkers and potential therapeutic targets in neurodegenerative disease. Front Genet. 2019;10:364.
25	25. Santamaria X, Taylor H. MicroRNA and gynecological reproductive diseases. FertilSteril. 2014;101:1545–51.
26	26. Ma, S.-G., Hu, J., & Huang, Y. (2020). The risk factors for perioperative venous thromboembolism in patients with gynecological malignancies: A meta-analysis. Thrombosis Research, 196, 325–334. doi:10.1016/j.thromres.2020.09.019
27	27. Kurt Benirschke, Peter Kaufmann. Pathology of the Human Placenta.doi: 10.1007/978-1-4757-4199-5_10.
28	28. Baldisserotto, M., Spolidoro, J. V. N., &Bahú, M. da G. S. (2002). Graded Compression Sonography of the Colon in the Diagnosis of Polyps in Pediatric Patients. American Journal of Roentgenology, 179(1), 201–205. doi:10.2214/ajr.179.1.1790201.
29	29. G L Grismondi, C Cetera, M Casetti. Polyps of the cervical canal.https://www.ncbi.nlm.nih.gov/pubmed/7366889.
30	30. Xi, L. F., Hughes, J. P., Edelstein, Z. R., Kiviat, N. B., Koutsky, L. A., Mao, C., … Schiffman, M. (2009). Human Papillomavirus (HPV) Type 16 and Type 18 DNA Loads at Baseline and Persistence of Type‐Specific Infection during a 2‐Year Follow‐Up. The Journal of Infectious Diseases, 200(11), 1789–1797. doi:10.1086/647993.
31	31. (1)Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today.
32	32. Xi, L. F., Hughes, J. P., Edelstein, Z. R., Kiviat, N. B., Koutsky, L. A., Mao, C., … Schiffman, M. (2009). Human Papillomavirus (HPV) Type 16 and Type 18 DNA Loads at Baseline and Persistence of Type‐Specific Infection during a 2‐Year Follow‐Up. The Journal of Infectious Diseases, 200(11), 1789–1797. doi:10.1086/647993.
33	33. Machalek, D. A., Garland, S. M., Brotherton, J. M. L., Bateson, D., McNamee, K., Stewart, M., … Tabrizi, S. N. (2018). Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination. The Journal of Infectious Diseases, 217(10), 1590–1600. doi:10.1093/infdis/jiy075.
34	34. Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., … Barr, E. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. The Lancet Oncology, 6(5), 271–278. doi:10.1016/s1470-2045(05)70101-7.
35	35. Matteson, K. A., &Zaluski, K. M. (2019). Menstrual Health as a Part of Preventive Health Care. Obstetrics and Gynecology Clinics of North America, 46(3), 441–453. doi:10.1016/j.ogc.2019.04.004
36	36. ACOG Committee Opinion No. 651: menstruation in girls and adolescents: using the menstrual cycle as a vital sign. ObstetGynecol 2015;126(6):e143–6.
37	37. ACOG annual well-woman exam infographic. Available at: https://www.acog.org/Patients/FAQs/Annual-Well-Woman-Exam-Infographic. Accessed January 4,2019.
38	38. Tingen CM, Mazloomdoost D, Halvorson L. Gynecologic health and disease research at the Eunice Kennedy Shriver National Institute of Child Health and Human Development, A scientific vision. ObstetGynecol 2018;132:987–98.
39	39. Munro M, Critchley H, Broder M, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J GynecolObstet 2011;113(1):3–13.
40	40. Munro MG, Critchley HO, Fraser IS, FIGO Menstrual Disorders Working Group. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years.FertilSteril 2011;95(7):2204–8.
41	41. Munro MG, Critchley HOD, Fraser IS, et al. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J GynecolObstet 2018;143(3):393–408.
42	42. Matteson KA, Boardman LA, Munro MG, et al. Abnormal uterine bleeding: a review of patient-based outcome measures. FertilSteril 2009;92(1):205–16.
43	43. Matteson KA, Scott DM, Raker CA, et al. The menstrual bleeding questionnaire: development and validation of a comprehensive patient-reported outcome instrument for heavy menstrual bleeding. BJOG 2015;122(5):681–9.